Pension funds invest 32.5 million Euro in controversial pharmaceutical firm

ZEMBLA has found that the ABP, PFZW, and SPH pension funds all hold shares in the controversial company. ABP has €27 million in Aurobindo shares, PFZW holds €5.2 million and SPH has invested €0.25 million. The three pension funds have told ZEMBLA that they are aware of and will take their responsibility regarding the situation with Aurobindo. SPH responds with the following statement: 'These findings are serious and are not in keeping with SPH's vision of socially responsible investment.'

Manufacturer of Dutch medicines exploit workers and pollute the environment

PZFW
PFZW states that it is involved with large pharmaceutical companies when it comes to environmental issues. This has not been the case with Aurobindo up until now. PFZW says it has called on other investors to intensify the pressure on Aurobindo.

ABP
ABP, which has invested in Aurobindo since mid 2014, says it will be in contact with the company's management. 'If it is revealed that Aurobindo employs unacceptable business practices, then we could sell off our investments in this company.'

Many of our cheap medicines are manufactured in developing countries such as India and China. ZEMBLA investigated the conditions in which cheap medicines are produced in India. In the ZEMBLA episode entitled The real price of cheap medicine , experts say that Aurobindo exploits its employees and causes substantial environmental pollution.